Some analyst comments on the non-approval from a Bloomberg update:
It's unclear what the FDA's concerns are, said Alex Zisson,
an analyst with Hambrecht & Quist who has a ''buy'' rating on
Pfizer.
''There's some thought that the FDA is really starting to
walk on eggshells now,'' following very public problems with
drugs such as Roche Holding AG's Posicor, pulled off the market
earlier this month because of its potential to have dangerous
interactions with other drugs, he said.
''The open question now is how much is Zeldox going to be
delayed?'' or whether it will hit the market at all, Zisson said.
Best case scenario would be that the FDA only wants further
analyses or information from ongoing studies, he said.
Still, because Pfizer has many profitable drugs, Zeldox
becomes less important, he said. ''In the scheme of things, even
if Zeldox completely goes away, it's not a tragedy,'' he said. |
